InnovAtlasMalaria No More
Research institution

University of Texas Southwestern Medical Center

DiscoverDevelop

UT Southwestern researchers develop antimalarial medicines that block essential parasite pathways, including DHODH and the proteasome, with the goal of treating and preventing malaria.

0
Endemic countries
1
U.S. states
2
Products and programs
About

What they do

UT Southwestern researchers develop antimalarial medicines that block essential parasite pathways, including DHODH and the proteasome, with the goal of treating and preventing malaria.1 Their U.S. R&D is based in Dallas, Texas.2,1 The work spans the discovery and development stages, from identifying new drug targets to optimizing oral DHODH inhibitors for long-acting chemoprevention; an earlier compound from the program, DSM265, reached Phase 2 trials.1

In the United States
Products and programs

In the field and in development

Plasmodium DHODH inhibitor program (DSM1465 series; DSM265 lineage)4,5,1
Plasmodium proteasome inhibitor project2,1
Where they work

Partnerships

No endemic-country partnerships are listed.

U.S. partners

Who they work with in the United States

  • Schrödinger, Inc.5,1
    New York, NY
  • NIH4,1
    Bethesda, MD · Funder · funder
Sources

Where this comes from

  1. 1Confirmed by the organization
  2. 2labs.utsouthwestern.edu
  3. 3labs.utsouthwestern.edu
  4. 4utsouthwestern.edu
  5. 5schrodinger.com